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eNOS expressionAbstract The anti-anginal effects of allopurinol were assessed in experimental model rats of angina
and their effects were evaluated with amlodipine. In the vasopressin-induced angina model, oral
administration of allopurinol in dose of 10 mg/kg revealed remarkably analogous effects in compar-
ison with amlodipine such as dose-dependent suppression of vasopressin-triggered time, duration
and severity of ST depression. In addition, allopurinol produced dose dependent suppression of
plasma Malondialdehyde (MDA) level, systolic blood pressure, cardiac contractility and cardiac
oxygen consumption; while in contrast, amlodipine minimally suppressed the elevation of plasma
MDA level. Endothelial NO synthase (eNOS) expression, serum nitrate were strikingly increased,
however lipid proﬁle was signiﬁcantly reduced. Seemingly, allopurinol was found to be more potent
than amlodipine – a calcium channel antagonist. To conclude, it was explicitly observed and veriﬁed
that on the ischemic electrocardiography (ECG) changes in angina pectoris model in rats, allopurinol
exerts a signiﬁcant protective effects, reminiscent of enhancement of vascular oxidative stress, func-
tion of endothelial cells, improved coronary blood ﬂow in addition to the potential enhancement in
myocardial stress. Moreover, our ﬁndings were in conformity with several human studies.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In majority of the epidemiological studies, a striking correla-
tion of escalating levels of uric acid in serum was observed
in addition to augmented cardiovascular event rate, further-
more the rise in the serum levels of uric acid was also found
to be associated with increase in the mortality in individuals
with recognized hazards of vascular disorders as well as nor-
mal healthy volunteers. Nevertheless, antioxidant properties
Figure 1 Induction of stable angina in rats.
488 Y.A. Al-Zahrani et al.of uric acid are well known, and few preclinical and clinical
studies proposed the protective effects of uric acid in neurode-
generative disorders. In contrast, considerable data exhibit to
sustain the harmful and prothrombotic effects of xanthine oxi-
dase, and this enzyme is well recognized as a signiﬁcant cause
of oxidative stress in the blood vessels, in addition to the impli-
cation of high levels of serum uric acid in the progress of car-
diovascular disorders. Basically, xanthine oxidase is a group of
enzymes, predominantly present in the liver, gastrointestinal
tract, kidney and brain. Nevertheless, its presence is revealed
all through the cardiovascular system (George and Struthers,
2008). Increased levels of proinﬂammatory cytokines and aug-
mentation of ischemia were revealed by expression of xanthine
oxidase and uric acid, Berry and Hare (2004) suggestive of
their implication in the inﬂammatory response which is a dis-
tinctive feature of atherosclerosis. Moreover, increased oxy-
genation of LDL (De scheerder et al., 1991), and augmented
release of the thrombolytic components such as 5HT, ATP
and ADP were also observed with uric acid (Ginsberg et al.,
1977). Xanthine oxidase enzymes can stimulate or initiate oxi-
dative stress by virtue of their property to release free radicals
of hydrogen oxide and hydrogen peroxide (Hille and Massey,
1981). The signiﬁcant role of uric acid to enhance in vitro pro-
duction was observed in rat vascular smooth muscle (Barberi
and Mene, 2006). In addition to its correlation with endothe-
lial dysfunction in hypertensive patients by means of its
enhanced impact on nitric oxide formation in the macula densa
(Mazzali et al., 2002; Saito et al., 1978; Dyer et al., 1999).
Fundamentally, allopurinol has a structural resemblance
with hypoxanthine and is rapid metabolism to oxypurinol,
and both of them work in a similar fashion. Their preferen-
tial binding to xanthine oxidase inhibits its activity (Elion,
1966). This in turn leads to lowering of both uric acid
and xanthine oxidase mediated free radical formation. All
these motivating ﬁndings have focused recent clinical
research on the utilization of the xanthine oxidase inhibitors
allopurinol and oxypurinol in the prevention of cardiovascu-
lar disorders.
Different studies of the inhibitory effects of xanthine have
revealed that, inhibition of xanthine oxidase signiﬁcantly
reduced the levels of oxidative stress in the circulation in indi-
viduals with heart failure (Doehner et al., 2002), diabetes
(Desco et al., 2002), metabolic syndrome (Yiginer et al.,
2008), obstructive sleep apnea (El Solh et al., 2006), coronary
artery disease (Eskurza et al., 2006), and liver disease
(Vuppalanchi et al., 2011). Furthermore, blood pressure was
improved in hypertensive individuals in response to xanthine
oxidase inhibition (Feig et al., 2008). A noteworthy ﬁnding
on reduction of ‘‘infarct size extension’’ was revealed in acute
coronary syndrome on treatment with allopurinol, neverthe-
less explanation of this ﬁnding seems to be complex in view
of methodological consideration (Parmley et al., 1992).
Finally, a large retrospective study recommended a protective
effect of high-dose allopurinol in comparison with low-dose
treatment; interestingly this study revealed that low-dose treat-
ment is as good as no treatment (Struthers et al., 2002). There-
fore, the intention of this paper is to examine the possible anti-
anginal effects of allopurinol compared with standard antian-
ginal drug, amlodipine, on the ST segment depression of ECG,
blood pressure, myocardial function, oxidative stress, eNOS
expression, serum uric acid and lipid proﬁle using ischemic
rats’ model with vasopressin.2. Materials and methods
2.1. Animal
89 Male Wistar strain rats (8–10 week old) were purchased
from the faculty of pharmacy, king Abdul Aziz University, Jed-
dah, Saudi Arabia. The animals were housed in animal house of
King Fahd Medical Research Center, King AbdulAziz Univer-
sity at a controlled temperature of 23–26 C under a 12 h light–
dark cycle with free access to food and water. All animals
received humane care in compliance with the ethical standards.
2.2. Drugs
Allopurinol and vasopressin (VP) were purchased from Sigma
(St. Louis, MO, USA). Amlodipine Tablets 5 mg were pur-
chased from Pﬁzer (Norvasc; USA). For the oral administra-
tion allopurinol and amlodipine were dissolved in sterile water
to a concentration of 10 mg/ml solution. For the intravenous
administration vasopressin was diluted in saline 0.9% to
1 IU/ml solution. The dose of amlodipine was 10 mg/kg
selected on the basis of a study conducted by (Sasaki et al.,
2005). Vasopressin dose was 2 IU/kg depended on the result
of pilot study. The doses of allopurinol were 35, 70, 105 mg/
kg selected according to the human therapeutic dose by using
conversion formula by (Freireich et al., 1966). Rats were
weighed weekly and the dose adjusted accordingly.
2.3. Induction of myocardial ischemia
Induction of ischemia was conducted based on a method of
(Hirata et al., 2005). Albino male rats were anesthetized using
pentobarbital (60 mg/kg), and then placed on a heating pad to
maintain temperature at 37 C with backs down. Polyethylene
I.V. cannula (26G · 19 mm) was inserted in the right lateral
vein of the tail. After stabilization period following the com-
pletion of the cannulation of polyethylene I.V. cannula, vaso-
pressin (VP) was intravenously injected at a dosage of 2 IU/kg
through the same cannula. The ST-segment depressionP 1 lv
was considered as an index of myocardial angina (Ikeda et al.,
2006), as shown in which recorded by the Powerlab system
(Model Figure). The recorded signals should be free of electri-
cal interference and noise. When the recording is over, the rats
were given time to wake up and then returned to their cages.
Antianginal effect of allopurinol in rats 489Each test took about one hour including the time of anesthetic
induction and recovery.
2.3.1. Measurement of the time to ST-Segment Depression,
duration and severity
30 Male rats (weighing 250–350 g) grouped to 5 groups; con-
trol n= 6, allopurinol 35 mg/kg n= 6, allopurinol 70 mg/kg
n= 6, allopurinol 105 mg/kg n= 6, amlodipine 10 mg/kg
n= 6. All drugs and vehicles were administrated orally once
daily for one month by gavage tube before the induction of
angina by vasopressin (VP). Experiments were performed
according to the method of Hirata et al. (2005)) and
Yamamoto et al. (2002), using the ST-segment an index of
myocardial ischemia ST-segment depression recorded by the
Powerlab system, Wistar strain rats were anesthetized with
pentobarbital (60 mg/kg, i.p.). Animals were placed on their
backs on a heating pad maintained at 370C. The right lateral
tail vein was cannulated with polyethylene (26G · 19 mm)
I.V cannula. After an adequate stabilization period following
completion of the cannulation, vasopressin (VP) was injected
intravenously at the dosage of 2 IU/kg.
2.3.2. Noninvasive blood pressure (NIBP) measurement
Fifty male albino rats of average weight 250–350 g were used.
Grouped into 5 groups; 10 rats each. Group I: non-treated
rats, group II, III, IV: allopurinol-treated rats (31, 62,
93 mg/kg/day respectively) and group V: amlodipine-treated
rats (10 mg/kg/day). All drugs and vehicles were adminis-
trated to the rats orally by gavages once daily for a period
of four weeks. The rats were restrained in the MLA5024
rat Restrainer at least 5–10 min prior to obtaining pressure
measurement. The tail was fully extended and exited through
the rear hatch opening of the holder. Darkened nose cone
into the rat restrainer to limit the animal’s view and reduce
the level of animal stress. Acclimatized rats will provide faster
BP measurements than non-acclimatized animals. A nervous,
stressed animal may have diminished circulation in the tail
(Menard et al., 2010). Blood pressure was measured by
Non-invasive Tail cuff method using the IN125/R NIBP Sys-
tem which was used in conjunction with a PowerLab system
to obtain non-invasive blood pressure measurement from
rats. NIBP utilizes a specialized tail cuff and pulse transducer
to intermittently measure blood pressure based on the peri-
odic occlusion of tail blood ﬂow (Zhao et al., 2009). Normal
blood pressures of all the rats were recorded as baseline
blood pressure and were recorded again after drug treatment
for four weeks.Table 1 Effect of daily oral administration of allopurinol versus am
and duration of vasopressin (2 IU/kg)-induced stable angina in an e
Treated groups Onset to ST-segment depression (s
Mean ± SEM %
Control (non-treated) 0 0
Control (vasopressin treated) 28.88 ± 1.302
Amlodipine 10 mg + vasopressin 48.50 ± 1.476*** 68%
Allopurinol 31 mg + vasopressin 32.75 ± 1.031### 13.
Allopurinol 62 mg + vasopressin 39.63 ± 0.865***,### 37.
Allopurinol 93 mg + vasopressin 43.88 ± 0.811***,# 52%
Values are expressed as the mean ± SEM; n= 10 rats; ***P< 0.001, c
###P< 0.001 compared with the corresponding amlodipine group values2.3.3. Cardiac contractility
For this part of the experiment, twenty-eight rats grouped to 3
groups; control n= 7, allopurinol 70 mg/kg n= 7, amlodipine
10 mg/kg n= 7. All drugs and vehicles were administrated
orally once daily for one month by gavage tube before the
administration of vasopressin (VP) to induce angina as pre-
scribed previous. Right carotid artery was catheterized with
Microcatheter connected to Power-lab system to continuous
record left ventricle contractility before and after vasopressin
injection.
2.3.4. Plasma Malondialdehyde (MDA) level
18 Male Wistar strain rats were randomized in three experi-
mental groups (n= 5 each). The ﬁrst experimental group
was given a small dose of allopurinol (35 mg/kg/day), second
group was given intermediate dose of allopurinol (70 mg/kg/
day) and the third experimental group was given a high dose
of allopurinol (105 mg/kg/day). Drug treatment period for
all experimental groups was 4 weeks. On 14, 21, 30 days of
treatment the blood sera were obtained from the Retro orbital
Puncture of rats from control group and from the three treat-
ment groups. Plasma samples for measuring MDA were frozen
immediately after sampling at 70 C until further processing.
The lipid peroxide content of the plasma studied by determin-
ing the thiobarbituric acid reactive substances (TBARS) for
the estimation of malondialdehyde (MDA) content using
Assay Kit (Catalog # KGE013).
2.3.5. Serum nitrate level
After four weeks of treatment blood sera from allopurinol and
control groups were obtained using retro-orbital puncture in
10-ml vacationer heparinized tubes. Immediately after sam-
pling, serum samples were frozen at a temperature of 70 C
for measuring nitrate using Colorimetric assay kit (Cayman
Chemical Item Number 780001) in a simple two-step process.
The ﬁrst one is the conversion of nitrate to nitrite utilizing
nitrate reductase. The second step is the addition of the Griess
reagents which convert nitrite into a deep purple azo com-
pound then measure the absorbance at 540 nm (Tsikas, 2007).
2.3.6. Endothelial Nitric Oxide Synthase (eNOS) Expression
In this part of experiment 20 Male Wistar strain rats were ran-
domly assigned to a control group (vehicle, sterile water) or
allopurinol group (70 mg/kg, dissolved in sterile water) admin-
istrated orally once daily for one month. Rats were sacriﬁced
24 h from the last dose, thoracic and abdominal aorta werelodipine for four weeks on the onset of ST-segment depression
xperimental albino rat.
econds) Duration of ST-segment depression (seconds)
Change Mean ± SEM % Change
0 0
385.38 ± 17.18
40.13 ± 6.53*** 89.6%
4% 350.88 ± 15.27### 9%
2% 166.50 ± 6.86***,### 56.8%
133.13 ± 6.44***,### 65.5%
ompared with the corresponding control group values; #P< 0.05,
; by one-way ANOVA and Bonferroni post hoc test.
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490 Y.A. Al-Zahrani et al.cut in segments (30 mg of each) and homogenized in liquid
nitrogen using a mortar and pestle, Total RNA will be
extracted by RNeasy Fibrous Tissue Mini Kit (cat. no.
74704) QIAGEN according to manufacturer’s instruction.
The RNA was treated with RNase-free DNase to remove
traces of genomic DNA contamination. Total RNA was then
reverse-transcribed to cDNA using the High Capacity cDNA
Reverse Transcription Kit and the target genes were ampliﬁed
using the standard real-time PCR kit (Applied Biosystems,
Foster City, CA, USA). The ampliﬁcation was performed in
real-time PCR system using Taqman probe. The fold
induction/repression in gene expression by real-time RT-PCR
was calculated after adjusting for actin using the formula
2DDCt. Primers used for ampliﬁcation of respective
gene were 5_-TTCCGGCTGCCACCTGATCCTAA-3_ and
5_ AACATGTGTCCTTGCTCGAGGCA-3_. The rat GAP-
DH primers will be 5-_TCCCTCCAGATTGTCAGCAA-3_
and 5_AGATCCACAACGGATACATT-3.
2.3.7. Lipid proﬁle
Blood samples were withdrawn at day 30 of treatment using
retro-orbital puncture in 10-ml vacationer tubes. Serum was
taken to determine serum uric acid level using colorimetric uric
Acid Assay Kit (Catalog #K608 BioVision) according to the
manufacture manual. Lipid proﬁle (Total cholesterol, Triglyc-
eride, High density lipoprotein and Low density lipoprotein)
level was measured using an enzyme colorimetric test (Pho-
tometer BTS-303; Biosystems, Barcelona, Spain).
2.4. Statistical analysis
All data shown were representing as the mean ± S.E.M. The
statistical signiﬁcance of difference between mean value from
control and treated groups were determined using SPSS (Statis-
tical package of social sciences version 20). One way analysis of
variance (ANOVA) and two-way analysis of variance
(ANOVA) followed by Bonferroni post hoc test, were used
for multiple comparisons. (p< 0.05, **p< 0.01, ***p< 0.001).
3. Results
3.1. Induction of myocardial ischemia
Model Figure shows that vasopressin-induced stable angina
model in an experimental albino rats based on a method of
Hirata et al. (2005) (Fig. 1).
3.2. Effect of allopurinol on ST-Segment Depression time,
duration and severity induced by vasopressin
Allopurinol in doses of (62 and 93 mg/kg/day) produced sig-
niﬁcant increase in the onset of ST-segment depression and sig-
niﬁcantly decreases in its duration compared to control
(Table 1). Moreover, a signiﬁcant decrease in the ST-segment
height at time of 0.5, 1, 3 and 6 min after vasopressin injection
was observed respectively (Table 2). However, a nonsigniﬁcant
effect on the onset, duration and height of ST-segment depres-
sion of allopurinol dose (31 mg/kg/day) was observed com-
pared to control group (P> 0.05). Furthermore, all
allopurinol doses (31, 62 and 93 mg/kg/day) exhibited a signif-
icant decrease in the onset to ST-segment depression and a sig-
Table 3 Effect of daily oral administration of allopurinol versus amlodipine for four weeks on noninvasive blood pressure in an
experimental albino rats.
Treated groups Systolic blood pressure (SBP, mm Hg)
Mean ± SEM % Change
Control (non-treated) 115 ± 0.55
Control (vasopressin treated) 120 ± 0.55*** 4%›
Amlodipine 10 mg + vasopressin 104.20 ± 1.1*** 9.5%ﬂ
Allopurinol 31 mg + vasopressin 113.5 ± 0.81### 1.3%ﬂ
Allopurinol 62 mg + vasopressin 110.4 ± 1.23**,### 4%ﬂ
Allopurinol 93 mg + vasopressin 110.1 ± 0.9**,### 4.3%ﬂ
Values are expressed as the mean ± SEM; n= 10 rats; **P< 0.01, ***P< 0.001, compared with the corresponding control group values;
###P< 0.001 compared with the corresponding amlodipine group values; by one-way ANOVA and Bonferroni post hoc test.
Antianginal effect of allopurinol in rats 491niﬁcant increase in the duration of ST-segment depression
respectively compared to amlodipine group (Tables 1 and 2).
However, a nonsigniﬁcant difference except at 0.5 and 1 min
after vasopressin injection was shown between allopurinol
(62 and 93 mg/kg/day) and amlodipine.
3.3. Effect of allopurinol on noninvasive blood pressure (NIBP)
measurement
Table 3 shows that allopurinol doses (62 and 93 mg/kg/day)
produced signiﬁcant decrease in systolic blood pressure com-
pared with control. While a nonsigniﬁcant change in systolic
blood pressure was observed with allopurinol (31 mg/kg/
day). Moreover, systolic blood pressure was signiﬁcantly
decreased in amlodipine group compared with allopurinol
and control groups.
3.4. Effect of allopurinol versus amlodipine on the Left
Ventricular Functions (LVF) of vasopressin -induced stable
angina
Administration of allopurinol (62 mg/kg/day) for four weeks
signiﬁcantly improved the vasopressin-induced reduction in
myocardial contractility at time 0.5 and 1 min after vasopres-
sin injection respectively and improved the vasopressin-
induced reduction in max rate of LV pressure (dP/dt) 15 min
after vasopressin injection (Table 4). Moreover, allopurinol
produced signiﬁcant decrease in heart rate at 0.5 min after
vasopressin injection with% change of 17.8% versus vasopres-
sin treated group. Furthermore, the difference in heat rate
between allopurinol and amlodipine was nonsigniﬁcant
(p> 0.05) at time 0.5, 1, 6, 15 min after vasopressin injection
(Table 5). Finally in Table 6 allopurinol signiﬁcantly decreased
myocardial oxygen consumption (% change of 5.7%) and sub-
stantially increased mechanical efﬁciency (% change of 31.5%)
compared with vasopressin and amlodipine treated group.
3.5. Effect of allopurinol on serum Malondialdehyde (MDA)
level
Table 7 shows that the level of MDA signiﬁcantly decreased
after 21 days of treatment with allopurinol (62 and 93 mg/
kg/day, p.o.) in comparison with baseline MDA level. This
reduction of MDA level was extremely increased in all allopu-
rinol treated groups (31, 62 and 93 mg/kg/day) after 30 days of
the treatment.3.6. Effect of allopurinol on serum nitrate level
Wealso sought to conﬁrm that allopurinol (62 mg/kg/day)med-
iated vasodilatation (Table 8) demonstrates that administration
of allopurinol for four weeks signiﬁcantly increased serum
nitrate level compared with vasopressin treated group with
mean ± SEM of 14.52 ± 0.55 and mean% change of 42.6%.
3.7. Effect of allopurinol on vasopressin-induced aortic eNOS
mRNA expression
Having established that allopurinol was able to regulate blood
pressure and left ventricular functions we then sought to iden-
tify through which proteins this effect might be mediated
(Table 9) show that the eNOS mRNA content in the aorta
as expressed by 2  DDCp which signiﬁcantly increased (%
change of 71%) as compared to the vasopressin-treated
groups.
3.8. Effect of allopurinol on the serum uric acid and lipid proﬁle
We then sought after to determine whether these effects are
linked also to uric acid and lipid concentration in the blood
serum. Table 10 shows that a signiﬁcant decrease in uric acid
(UA), triglyceride (TG), Low density lipoprotein (LDL) levels
respectively after four weeks of allopurinol (62 mg/kg/day)
administration compared with control group with mean%
change of 26.6%, 7.7%, and 51.2% respectively while no sig-
niﬁcant change in total cholesterol (TC) and high density lipo-
protein (HDL) with mean% change of 0.5 and 0.9 respectively.
4. Discussion
In the present study, we have demonstrated that long-term
treatment with step-dose allopurinol (31, 62 and 93 mg/kg/
day) is equivalent to human therapeutics doses of 300, 600
and 900 mg/day respectively. Yet these doses, which are lower
or equal a maximum dose (900 mg/day) allowed by British
National Formulary (Noman et al., 2010), for more four
weeks, have signiﬁcantly prolonged time to develop ST – seg-
ment depression and suppressed effects on the duration and
severity of ST-segment depression in vasopressin-induced
ischemia model in rats compared with control group. Some
of ﬁndings of our present study have been demonstrated in a
few fundamental human works. In fact the American College
Table 4 Effect of daily oral administration of allopurinol versus amlodipine for four weeks on the myocardial contractility and (max dP/dt) of vasopressin induced angina.
Control (non-treated) Treated groups
Control
(vasopressin-treated)
Amlodipine
10 mg + vasopressin
Allopurinol
62 mg + vasopressin
A. Myocardial contractility
0.5 min. after vasopressin injection Mean ± SEM 162.34 + 14 78.04 ± 12.3 130.37 ± 13 162.07 ± 15**
% Change 74.4% 107.7%
1 min. after vasopressin injection Mean ± SEM 155.14 + 11.2 71.24 ± 16.4 130.1 ± 18* 144.16 ± 21*
% Change 82.6% 102.3%
6 min. after vasopressin injection Mean ± SEM 160.02 + 13 117.4 ± 14.7 123 ± 16.1 154.2 ± 1
% Change 4.8% 31%
15 min. after vasopressin injection Mean ± SEM 148.38 + 16 117.7 ± 19.8 127.2 ± 21 143.1 ± 24.2
% Change 8% 21.6%
B. The maximum rate of LV pressure rise (max dP/dt)
0.5 min. after vasopressin injection Mean ± SEM 12082.06 ± 65 8750 ± 1089 10887 ± 1098 10893 ± 1101
% change 24.4% 24.5%
1 min. after vasopressin injection Mean ± SEM 12104 ± 125 8584 ± 950 10684 ± 900 10801 ± 980
% change 24.5% 25.6%
6 min. after vasopressin injection Mean ± SEM 12263.401 11204 ± 288 11250 ± 300 11382 ± 305
% change 0.4% 1.6%
15 min. after vasopressin injection Mean ± SEM 12144.637 9185 ± 807 12360 ± 800 12762 ± 850*
% change 34.6% 40%
Values are expressed as the mean ± SEM; n= 7 rats; *P< 0. 05, **P< 0.01, compared with the corresponding control group values compared with the corresponding amlodipine group values; by
two-way ANOVA and Bonferroni post hoc test.
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Antianginal effect of allopurinol in rats 493of Cardiology guidelines on chronic angina mention allopuri-
nol as a possible antianginal drug based on this Lancet paper
(Noman et al., 2010). Secondly, an explanation for this anti-
ischemic effect in human comes from other study which shows
that allopurinol reduces LV volumes especially LV end systolic
volume (Halcox et al., 2002). This illustrates that allopurinol
off-loads the heart and ofﬂoading the heart is a common
way by which the antianginal drugs work. Furthermore, our
results are in accordance with other study, which has revealed
that allopurinol reduced troponin release during ST-elevation
myocardial infarction (Rekhraj et al., 2013). The magnitude
increase in median time to ST depression with allopurinol
seems to be quite similar to that noted in other studies with
other anti-anginal drugs such as amlodipine 36 s (13%)
(Knight and Fox, 1998) and 60 s (11%) with nitrates
(Knight and Fox, 1998), 12–47 s (4–14%) with phosphodies-
terase inhibitors (Thadani et al., 2002), 46 s (13.5%) with Iva-
bradine (Tardif et al., 2009), and about 50 s (15%) with
Atenolol and Ranolazine (Rousseau et al., 2005). In current
study the absolute increase in median time to ST depression
with allopurinol was 43 s (19% increases).
The potential mechanism of the antianginal effect of allo-
purinol needs to be explained and substantiated in the light
of several relevant observations, the capability of allopurinol
to reduce myocardial oxygen consumption for the stroke vol-
ume (Ekelund et al., 1999). This can be explained on the basis
of decrease in oxidative stress, as xanthine oxidase is well rec-
ognized to utilize molecular oxygen to produce oxidative
stress, and therefore blockade of this enzyme prevents oxygen
expenditure, which in turn ampliﬁes the molecular supply of
the oxygen in ischemic myocardium (Mellin et al., 2005).
Moreover, Saavedra et al. (2002) elucidated that oxidative
stress by itself could directly produce an anti- ischemic effect.
Xanthine oxidase breaks down substrates for ATP, such as
AMP; hence inhibition of this enzyme enhances ATP a high
energy phosphate which is essential to provide energy to
depleted ischemic tissues. This is suggestive of using allopuri-
nol as a medication that can increase the oxygen and high-
energy phosphates (ATP) in ischemic cardiac tissue. Besides,
we have shown that allopurinol signiﬁcantly decreases systolic
blood pressure suggesting that the elevation of serum uric acid
level contributes to vasopressin induced angina in rats.
This ﬁnding was in resemblance with other study which
associates escalating levels of uric acid in the serum with con-
comitant augmented cardiovascular event rate and mortality in
those individuals with recognized or high risk of vascular dis-
ease (Alderman, 2002; Forman et al., 2007; Stull et al., 2004;
Khan et al., 2008). Remarkably several studies had linked uric
acid in the genesis of hypertension and the use of allopurinol
alone in recently diagnosed hypertensive adolescent has led
to correction of blood pressure (Sathisha et al., 2011).
Our left ventricular function data offer interesting clues
regarding the other possible mechanisms. Our study had dem-
onstrated that, allopurinol produced a signiﬁcantly improved
vasopressin-induced reduction in myocardial contractility after
ischemia induction, and in max dp/dt (as an indicator of LV
contractile performance), decreased heart rate, decreased myo-
cardial oxygen consumption and substantially increased
mechanical efﬁciency (as an indicator of work done by heart).
These results are consistent with the ability of XO inhibitors to
improve myocardial efﬁciency (Max dp/dt)/MVO2) by acting
as calcium sensitizers in vitro since the improvement in myo-
Table 6 Effect of daily oral administration of allopurinol versus amlodipine for four weeks on the myocardial oxygen consumption
(MVO2) and cardiac efﬁciency in vasopressin (2 IU/kg)-induced angina in albino rats.
Treated groups Mean ± SEM % Change
A. Myocardial oxygen consumption (MVO2)
Control (non-treated) 60788 ± 112
Control (vasopressin-treated) 61198 ± 148
Amlodipine 10 mg + vasopressin 60792 ± 108 0.66%
Allopurinol 62 mg + vasopressin 57681 ± 257***,### 5.7%
B. Cardiac eﬃciency
Control (non-treated) 0.19 ± 0.102
Control (vasopressin-treated) 0.19 ± 0.027
Amlodipine 10 mg/kg/day 0.20 ± 0.055** 5.3%
Allopurinol 62 mg/kg/day 0.25 ± 0.062***,### 31.5%
Values are expressed as the mean ± SEM; n= 7 rats; **P< 0.01, ***P< 0.001, compared with the corresponding control group values;
###P< 0.001 compared with the corresponding amlodipine group values by two-way ANOVA and Bonferroni post hoc test.
494 Y.A. Al-Zahrani et al.cardial oxidative stress enhances myoﬁlament responsiveness
to activator calcium and this in turn enhances the impaired
myocardial energy utilization which is a characteristic feature
of heart failure (Laursen et al., 2001). It needs to be highlighted
that both acute and chronic administration of allopurinol aug-
ments contractility of myocardium in experimental animals
with heart failure, with simultaneous reduction in myocardial
oxygen consumption (Saavedra et al., 2002).
A possible explanation to this effect, could be attributed to
superoxide generated with xanthine oxidase obstructs with
intracellular signals which are essential regulators of energy
metabolism, a prototype depicting nitric oxide regulates the
enzymes implicated in ATP formation and storage through
creatine phosphokinase, and consumption of energy by cardiac
myocyte calcium cycling. Furthermore, rapid reaction of
superoxide (O2) with nitric oxide could also interrupt these
signaling conduits, and eventually leads to disturbance of
energy metabolism with ultimate reduction in efﬁciency. More-
over, nitric oxide (NO) and superoxide (O2) act synergisti-
cally to form peroxynitrite (ONOO) (Beckman and
Koppenol, 1996). Thus, it is possible that enhanced production
of both NO and O2 in angina contributes to the generation
of ONOO–, this may explains the signiﬁcant decline in cardiac
contractility in control group compared with allopurinol group
after ischemia induction in the present study. Another study in
support of this ﬁnding, proposed that allopurinol diminishes
the augmentation index indicating a reduction of left ventricu-
lar afterload (Lockette et al., 1986).
The rationalization for implication of xanthine oxidase is
substantially clear by the ﬁnding of our study in which allopu-
rinol has been shown to remarkably decreased oxidative stress,
in all treated group after 30 days of treatment. These results
indicate that xanthine oxidase is a major source for this oxida-
tive stress due to decreased xanthine oxidase induced oxidative
stress in treated groups by allopurinol. Vascular oxidative
stress is quite distinguished as an essential pathobiological
expression of Coronary artery disease. Our observation may
perhaps well contribute mechanistically to the anti-ischemic
action of allopurinol in pathogenesis of angina. In reality, xan-
thine oxidase is well recognized to utilize enormous amount of
oxygen by its ability to produce superoxide anions and hydro-
gen peroxide in addition to the fact that the main xanthine oxi-
dase substrate (hypoxanthine) has only one oxygen/molecule,while on the contrary its main xanthine oxidase product, uric
acid, has three oxygen/molecule (Harrison, 2002).
It is well known that in atherosclerosis, diabetes mellitus,
heart failure and microthrombus formation, endothelial dys-
function is regarded as the main early characteristic feature.
Therefore, the present study exclusively affords the earliest
direct authentication that the chronic use of allopurinol in rats
resulted in Upregulation of thoracic aortic eNOS mRNA and
subsequent increases in serum nitrate bioavailability. However,
the mechanisms underlying the increased expression of eNOS
in response to allopurinol shown in the present study remain
uncertain. Many studies have demonstrated that the degrada-
tion of NO by ROS in many animal models of hypertension,
diabetes and heart failure (Harrison, 2002). There are several
potential mechanisms contribute to decline in NO bioavailabil-
ity e.g., reduction in eNOS expression, reduction in eNOS
activity, and rapid degradation in NO by reactive oxygen spe-
cies (ROS) (Tseng, 2004).
The downregulation of nitric oxide synthase is quite illustri-
ous in ischemic tissues; allopurinol seems to be essentially ben-
eﬁcial due to the fact that it can satisfactorily alter both
enzymes. Seemingly, the distinct effect of allopurinol to reduce
the vascular oxidative stress is relatively exciting, how far this
could be transformed into clinical vascular protection is still
not clear, and needs further crucial studies. The correlation
of raised levels of uric acid in serum and coronary artery dis-
ease is well documented in several studies (Suliman et al.,
2006). Furthermore, it is also revealed that alteration in uric
acid abundantly effects the lipid levels, this in turn transforms
the cardiovascular outcomes attributable to deranged endothe-
lial dependent vasodilatation by virtue of lipid oxidation.
A large number of studies have highlighted on the risk of
metabolic syndrome, in contrast very few of them attempted
to focus the relationship involving uric acid and lipids
(Shelmadine et al., 2009). Our present study has demonstrated
that the effect on serum lipid proﬁle (SLP) on chronic admin-
istration of allopurinol for four weeks, signiﬁcant fall in serum
triglyceride (TG) and low density lipoprotein (LDL) was
observed, whereas no signiﬁcant alteration was detected in
serum total cholesterol (TC) as well as high density lipoprotein
(HDL).
The elucidation of the mechanism of beneﬁcial lipid regula-
tion by the uric acid seems to be controversial, nevertheless
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Antianginal effect of allopurinol in rats 495proposed mechanism incorporates inhibition of lipid peroxi-
dase and reduction in decisive activity of lipoprotein lipase,
an essential enzyme linked together with lipolysis of triglycer-
ides as well as oxidation of LDL-C (Sasaki et al., 2005; Jelic-
Ivanovic et al., 2007). The present results are also in agreement
with ﬁndings obtained by other investigators who have shown
that there was no association between TC and HDL and uric
acid level (Beltrame et al., 2009). Notwithstanding, there is still
a dilemma, either uric acid is a cause or an outcome or merely
an indicator of cardiovascular disease (Fraker et al., 2007).
Further exploration is required to determine the potential role
of uric acid in the genesis of ischemic heart disease. A substan-
tial reduction in quality of life is attributed to chronic stable
angina, since one out of three patients develops angina no less
than once a week (Beltrame et al., 2009). Furthermore, several
patients are still incapable to fulﬁll the guideline aspiration of
the American College of Cardiology and American Heart
Association of total absence of exertional angina episodes
(Fraker et al., 2007).
Consequently, innovative treatments are required, allopuri-
nol could now be considered as a safe potential alternative
drug for angina. It has several advantages in comparison with
other recently added drugs such as Ranolazine and Ivabradine.
It has a signiﬁcant safety proﬁle of more than 40 years for the
treatment of gout. In contrast to established old drugs for
angina (nitrates and b receptor antagonists), allopurinol seems
to be better tolerated by virtue of insigniﬁcant effect on blood
pressure and heart rate in addition to lack of other collateral
effect such as headache and tiredness which are frequently
observed with nitrates and b blockers. Therefore, more data
are needed to compare and contrast the use of allopurinol withTable 8 Effect of daily oral administration of allopurinol
(62 mg/kg/day) for four weeks on serum nitrate level in an
experimental albino rats.
Treated groups Serum Nitrate level (lmol/ml)
Mean ± SEM % Change
Control (non-treated) 12.08 ± 0.53
Control (vasopressin-treated) 10.18 ± 0.81
Allopurinol 62 mg/kg/day 14.52 ± 0.55*** 42.6%
Values are expressed as the mean ± SEM; n= 6 rats; ***P< 0.001
compared with the corresponding control group values; by
unpaired t-test.
Table 9 Effect of daily oral administration of allopurinol for
four weeks on the expression of endothelial nitric oxide
synthase (eNOS) gene in experimental albino rats.
Treated groups Expression of endothelial nitric oxide
synthase (eNOS) 2DDCt
Mean ± SEM % Change
Control (non-treated) 0.605 ± 0.05
Control (vasopressin-treated) 0.525 ± 0.03
Allopurinol 62 mg/kg/day 0.897 + 0.03*** 71%
Values are expressed as the mean ± SEM; n= 10 rats;
***P< 0.001 compared with the corresponding control group
values; by unpaired t-test.
Table 10 Effect of daily oral administration of allopurinol for four weeks on serum uric acid and lipid proﬁle levels in an experimental
albino rats.
Treated groups
Control (non-treated) Control (vasopressin-treated) Allopurinol 62 mg/kg/day
Uric acid (mg/dl) Mean ± SEM 1.45 ± 0.22 1.62 ± 0.28 0.79 ± 0.12*
% Change 51.2% ﬂ
Total cholesterol (TC) (mg/dl) Mean ± SEM 119.52 + 2.2 119.4 ± 2.36 118.8 ± 2.02
% Change 0.5% ﬂ
Triglyceride (TG) (mg/dl) Mean ± SEM 63 ± 1.23 65 ± 1.03 60 ± 1**
% Change 7.7% ﬂ
High density lipoprotein (HDL) (mg/dl) Mean ± SEM 54.98 ± 1.31 54.96 ± 1.28 55.46 ± 1.35
% Change 0.9% ›
Low density lipoprotein (LDL) (mg/dl) Mean ± SEM 11.87 ± 1.20 13.54 ± 1.04 9.94 ± 0.60*
% Change 26.6% ﬂ
Values are expressed as the mean ± SEM; n= 6 rats; *P< 0.05, **P< 0.01 compared with the corresponding control group values; by
unpaired t-test.
496 Y.A. Al-Zahrani et al.other established treatment options in patients with angina.
Moreover, potential side effects of allopurinol were not studied
in the present studies and further research is needed. In view of
the ﬁndings of our study, allopurinol seems to be quite valu-
able option for the treatment of angina, with a distinct advan-
tages of well compliance, safety and economical. Further
exploration is required for deﬁning the status of allopurinol
in the management of angina e.g., the plasma renin activity
to elucidate the effect of allopurinol on blood pressure. More-
over, it may be valuable to use transgenic or knockout mice
model of a xanthine oxidase to exclude the direct effect of uric
acid. Moreover, molecular mechanism of action suggested in
our study needs further studies for precise authentication. In
order to conﬁrm our results additional large prospective, ran-
domized, placebo-controlled studies are required. The limita-
tion is that the present study demonstrated only the data at
the acute phase by the 15 min after vasopressin injection,
therefore, the effect of allopurinol on chronic myocardial dam-
age in rats and ST segment depression should be evaluated.
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